SANOFI ILAC SANAYI VE TICARET ANONIM SIRKETI

Lupin has entered into a strategic licensing and supply agreement with Czech-based Zentiva to commercialize its biosimilar version of Certolizumab Pegol across multiple global markets.

• Cinclus Pharma has partnered with Zentiva to commercialize linaprazan glurate, a next-generation potassium-competitive acid blocker (PCAB) for severe erosive GERD, in a deal valued at €220 million. • The agreement includes an upfront payment of €13 million, with Cinclus eligible for milestone payments and tiered double-digit royalties starting in the high teens and potentially exceeding 20%. • Cinclus Pharma plans to initiate its first Phase III study for linaprazan glurate in Q3 2025, targeting an addressable market of approximately 19 million patients globally.

The Unified Patent Court has denied Boehringer Ingelheim International's request for provisional measures against Zentiva regarding generic nintedanib medicines for lung fibrosis and cancer treatment.

• Biocon and Zentiva have secured EU approval via the Decentralized Procedure for their generic liraglutide formulation. • The approval covers generic versions of Victoza for treating Type-2 Diabetes and Saxenda for weight management. • This approval allows for the drug's sale across EU member states without requiring centralized authorization. • Liraglutide addresses the rising global prevalence of Type 2 diabetes and the need for effective weight management solutions.

Biocon and Zentiva have received EU approval for their generic Liraglutide formulation via a decentralized procedure, targeting Type-2 Diabetes and weight management.

The EU Council has formally adopted the Urban Wastewater Treatment Directive (UWWTD), introducing new financial obligations for pharmaceutical companies to remove micropollutants from effluent water.